New Treatment to Remove Clots Offers Dramatic Results
A new interventional radiology procedure to treat blood clots does not require the use of thrombolytic agents – clot-busting medicines that can result in bleeding elsewhere in the body. This expands the ability to treat older patients, or patients with other medical issues who are at a higher risk for bleeding.
Crosstalk between cells plays role in pulmonary hypertension
Pulmonary hypertension is a type of high blood pressure that affects blood vessels in the lungs. Once diagnosed, patients have limited treatment options, and many do not live beyond seven years. In a new study, scientists in the Yale Cardiovascular Research Center have gained new insight into the development of the disease that could lead to new therapies.
Yale Recognized as FARE Clinical Care Center of Distinction
Yale School of Medicine's Pediatric Allergy and Immunology Division — housed under the section of Pediatric Pulmonology, Allergy, Immunology & Sleep Medicine in the Department of Pediatrics — has been named a FARE Clinical Care Center of Distinction by Food Allergy Research & Education (FARE).
We wanted to take an opportunity and communicate to you that our entire Yale PCCSM team have been awestruck by the courage and esprit de corps exhibited by so many of our YSM colleagues have joined forces with us to help care for the increasing numbers of critically ill COVID-19 patients in our units.
Meet Yale Internal Medicine: Vivian Asare, MD, Assistant Professor of Medicine (Pulmonary, Critical Care, and Sleep Medicine).
As part of our “Meet Yale Internal Medicine” series, today’s featured physician is Vivian Asare, MD, assistant professor of medicine (pulmonary, critical care, and sleep medicine).
With Cellular Blueprint for Lungs, Yale Researchers Look Ahead to Organ Regeneration
Using sophisticated screening across animal species, researchers at Yale have created a cellular blueprint of the human lung that will make it easier to understand the design principles behind lung function and disease — and to bioengineer new lungs. The research, published Dec. 4 in Science Advances, represents a collaboration between two Yale labs — that of Naftali Kaminski, M.D., chief of pulmonary, critical care, and sleep medicine at Yale School of Medicine, and Laura Niklason, M.D., Ph.D., the Nicholas Greene Professor of anesthesiology and biomedical engineering and an expert in stimulating growth of new lung tissue from the body’s own cells for use in transplants.
Yale Study Provides Insights Into How Fibrosis Progresses in the Human Lung
A Yale-led collaborative study boosts scientific understanding of how the lung disease idiopathic pulmonary fibrosis (IPF) progresses, providing a roadmap for researchers to discover new treatment targets for the disease.
Moving Toward Family-friendly Intensive Care Units
As with other forms of health care, there is increasing desire by patients and their loved ones to be more involved in what happens in hospital intensive care units (ICUs). But it is possible this desire can clash with pressures that are inherent in caring for patients whose health is so precarious, and ingrained routines that ICU staff often embrace. Yale clinicians, in a study published in Critical Care Medicine, collaborated with the Society of Critical Care Medicine (SCCM) to demonstrate potential routes for making intensive care more patient- and family-centered.
Respiratory Experts Fight for Climate Change Measures
In the paper “Climate change and lung health – presidential failure, professional responsibility,” respiratory experts are again voicing their concern regarding the environmental policies of President Donald Trump and its connection to lung health.
New test could lead to personalized treatments for cystic fibrosis
Cystic fibrosis is a devastating disease caused by mutations in a specific gene, known as the CFTR gene. But not everyone with cystic fibrosis has the same symptoms or responds to drug treatments in the same way. In a new pilot study, researchers from the University of Cambridge and Yale University developed a novel, straightforward way to test multiple drugs on cells obtained from individual patients with cystic fibrosis, raising the possibility of highly personalized drug treatment.